Trial Profile
Phase II clinical study of adherence to dasatinib in Japanese patients with de novo chronic phase chronic myeloid leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2020
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ADAM 01
- 05 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 25 Jan 2013 New trial record